151 related articles for article (PubMed ID: 11966665)
1. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
Dingemanse J; Clozel M; van Giersbergen PL
Br J Clin Pharmacol; 2002 Apr; 53(4):355-62. PubMed ID: 11966665
[TBL] [Abstract][Full Text] [Related]
2. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist.
Dingemanse J; Clozel M; van Giersbergen PL
J Cardiovasc Pharmacol; 2002 Jun; 39(6):795-802. PubMed ID: 12021573
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
Torre-Amione G; Young JB; Durand J; Bozkurt B; Mann DL; Kobrin I; Pratt CM
Circulation; 2001 Feb; 103(7):973-80. PubMed ID: 11181472
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.
Dingemanse J; Gunawardena KA; van Giersbergen PL
Br J Clin Pharmacol; 2006 Apr; 61(4):405-13. PubMed ID: 16542201
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist.
van Giersbergen PL; Bodin F; Dingemanse J
Eur J Clin Pharmacol; 2002 Jul; 58(4):243-5. PubMed ID: 12136369
[TBL] [Abstract][Full Text] [Related]
6. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
van Giersbergen PL; Dingemanse J
Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
[TBL] [Abstract][Full Text] [Related]
7. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan.
Dingemanse J; Halabi A; van Giersbergen PL
J Clin Pharmacol; 2009 Apr; 49(4):455-64. PubMed ID: 19318695
[TBL] [Abstract][Full Text] [Related]
8. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan.
van Giersbergen PL; Dingemanse J
Int J Clin Pharmacol Ther; 2003 Jun; 41(6):261-6. PubMed ID: 12816178
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.
Lebrec D; Bosch J; Jalan R; Dudley FJ; Jessic R; Moreau R; Garcia-Pagan JC; Mookerjee RP; Chiossi E; Van Giersbergen PL; Kusic-Pajic A; Dingemanse J
Eur J Clin Pharmacol; 2012 May; 68(5):533-41. PubMed ID: 22101624
[TBL] [Abstract][Full Text] [Related]
10. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure.
Torre-Amione G; Durand JB; Nagueh S; Vooletich MT; Kobrin I; Pratt C
Chest; 2001 Aug; 120(2):460-6. PubMed ID: 11502644
[TBL] [Abstract][Full Text] [Related]
11. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G; Young JB; Colucci WS; Lewis BS; Pratt C; Cotter G; Stangl K; Elkayam U; Teerlink JR; Frey A; Rainisio M; Kobrin I
J Am Coll Cardiol; 2003 Jul; 42(1):140-7. PubMed ID: 12849674
[TBL] [Abstract][Full Text] [Related]
13. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model.
Hedelin P; Kylhammar D; Rådegran G
Acta Physiol (Oxf); 2012 Mar; 204(3):419-34. PubMed ID: 21726419
[TBL] [Abstract][Full Text] [Related]
14. Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep.
Kuklin VN; Kirov MY; Evgenov OV; Sovershaev MA; Sjöberg J; Kirova SS; Bjertnaes LJ
Crit Care Med; 2004 Mar; 32(3):766-73. PubMed ID: 15090960
[TBL] [Abstract][Full Text] [Related]
15. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
O'Connor CM; Gattis WA; Adams KF; Hasselblad V; Chandler B; Frey A; Kobrin I; Rainisio M; Shah MR; Teerlink J; Gheorghiade M;
J Am Coll Cardiol; 2003 May; 41(9):1452-7. PubMed ID: 12742280
[TBL] [Abstract][Full Text] [Related]
16. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans.
Treiber A; Van Giersbergen PL; Dingemanse J
Xenobiotica; 2003 Apr; 33(4):399-414. PubMed ID: 12745875
[TBL] [Abstract][Full Text] [Related]
18. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock.
Konrad D; Oldner A; Rossi P; Wanecek M; Rudehill A; Weitzberg E
Crit Care Med; 2004 May; 32(5):1192-9. PubMed ID: 15190972
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.
Clozel M; Ramuz H; Clozel JP; Breu V; Hess P; Löffler BM; Coassolo P; Roux S
J Pharmacol Exp Ther; 1999 Aug; 290(2):840-6. PubMed ID: 10411600
[TBL] [Abstract][Full Text] [Related]
20. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Kaluski E; Kobrin I; Zimlichman R; Marmor A; Krakov O; Milo O; Frey A; Kaplan S; Krakover R; Caspi A; Vered Z; Cotter G
J Am Coll Cardiol; 2003 Jan; 41(2):204-10. PubMed ID: 12535809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
